Enter the controversial world of genetic engineering. It covers all facets of DNA cloning through stem cell research, gene splicing for feature alterations and genetically engineered foods with more or less desirable properties. But there's a brighter side to this dark laboratory science: much of the research goes towards medicinal value, particularly for human beings. Some people argue that unravelling the mysteries sof the double-helix may be the key to understanding the design for life on Earth and to prolongeth life, health and prosperity. Others say that tampering with God's design is foolish and that the ends do not justify the means. What do you say..? Find out the latest and greatest of what's going on in the rapidly expanding world at INReview's discussion forum on the matter!
A framework for discussing the issue was provided by Center Director
of Biotechnology and Health Care Ethics Margaret McLean, who also serves
on the California State Advisory Committee on Human Cloning. In 1997,
the California legislature declared a "five year moratorium on cloning
of an entire human being" and requested that "a panel of representatives
from the fields of medicine, religion, biotechnology, genetics, law, bioethics
and the general public" be established to evaluate the "medical,
ethical and social implications" of human cloning (SB 1344). This
12-member Advisory Committee on Human Cloning convened five public meetings,
each focusing on a particular aspect of human cloning: e.g., reproductive
cloning, and cloning technology and stem cells. The committee is drafting
a report to the legislature that is due on December 31, 2001. The report
will discuss the science of cloning, and the ethical and legal considerations
of applications of cloning technology. It will also set out recommendations
to the legislature regarding regulation of human cloning. The legislature
plans to take up this discussion after January. The moratorium expires
the end of 2002.
What should the state do at that point? More than 80 invited guests came
to SCU for "California Cloning" to engage in a dialogue on that
question. These included scientists, theologians, businesspeople from
the biotechnology industry, bioethicists, legal scholars, representatives
of non-profits, and SCU faculty. Keynote Speaker Ursula Goodenough, professor
of biology at Washington University and author of Genetics, set
the issues in context with her talk, "A Religious Naturalist Thinks
About Bioethics." Four panels addressed the specific scientific,
religious, ethical, and legal implications of human reproductive cloning
and stem cell research. This document gives a brief summary of the issues
as they were raised by the four panels.
Science and Biotechnology Perspectives
Thomas Okarma, CEO of Geron Corp., launched this panel with an overview
of regenerative medicine and distinguished between reproductive cloning
and human embryonic stem cell research. He helped the audience understand
the science behind the medical potential of embryonic stem cell research,
with an explanation of the procedures for creating stem cell lines and
the relationship of this field to telomere biology and genetics. No brief
summary could do justice to the science. The reader is referred to the
report of the National Bioethics Advisory Committee (http://bioethics.georgetown.edu/nbac/stemcell.pdf)
for a good introduction.
Responding to Okarma, were J. William Langston, president of the Parkinsons
Institute, and Phyllis Gardner, associate professor of medicine and former
dean for medical education at Stanford University. Both discussed the
implications of the presidents recent restrictions on stem cell
research for the non-profit sector. Langston compared the current regulatory
environment to the Reagan era ban on fetal cell research, which he believed
was a serious setback for Parkinsons research. He also pointed out
that stem cell research was only being proposed using the thousands of
embryos that were already being created in the process of fertility treatments.
These would ultimately be disposed of in any event, he said, arguing that
it would be better to allow them to serve some function rather than be
destroyed. President Bush has confined federally-funded research to the
64 existing stem cell lines, far too few in Langstons view. In addition,
Langston opposed bans on government funding for stem cell research because
of the opportunities for public review afforded by the process of securing
government grants.
Gardner talked about the differences between academic and commercial
research, suggesting that both were important for the advancement of science
and its application. Since most of the current stem cell lines are in
the commercial sector and the president has banned the creation of new
lines, she worried that universities would not continue to be centers
of research in this important area. That, she argued, would cut out the
more serendipitous and sometimes more altruistic approaches of academic
research. Also, it might lead to more of the brain drain represented by
the recent move of prominent UCSF stem cell researcher Roger Pedersen
to Britain. Gardner expressed a hope that the United States would continue
to be the "flagship" in stem cell research. Her concerns were
echoed later by moderator Allen Hammond, SCU law professor, who urged
the state, which has been at the forefront of stem cell research to consider
the economic impact of banning such activity. All three panelists commended
the decision of the state advisory committee to deal separately with the
issues of human cloning and stem cell research.
Religious Perspectives
Two religion panelists, Suzanne Holland and Laurie Zoloth, are co editors
of The Human Embryonic Stem Cell Debate: Science, Ethics and Public
Policy (MIT Press, 2001). Holland, assistant professor of Religious
and Social Ethics at the University of Puget Sound, began the panel with
a discussion of Protestant ideas about the sin of pride and respect for
persons and how these apply to human reproductive cloning. Given current
safety concerns about cloning, she was in favor of a continuing ban. But
ultimately, she argued, cloning should be regulated rather than banned
outright. In fact, she suggested, the entire fertility industry requires
more regulation. As a basis for such regulation, she proposed assessing
the motivation of those who want to use the technology. Those whose motives
arise from benevolence--for example, those who want to raise a child but
have no other means of bearing a genetically related baby--should be allowed
to undergo a cloning procedure. Those whose motives arise more from narcissistic
considerations -- people who want immortality or novelty -- should be
prohibited from using the technology. She proposed mandatory counseling
and a waiting period as a means of assessing motivation.
Zoloth reached a different conclusion about reproductive cloning based
on her reading of Jewish sources. She argued that the availability of
such technology would make human life too easily commodified, putting
the emphasis more on achieving a copy of the self than on the crucial
parental act of creating "a stranger to whom you would give your
life." She put the cloning issue in the context of a system where
foster children cannot find homes and where universal health care is not
available for babies who have already been born. While Zoloth reported
that Jewish ethicists vary considerably in their views about reproductive
cloning, there is fairly broad agreement that stem cell research is justified.
Among the Jewish traditions she cited were:
-
The embryo does not have the status of a human person.
-
There is a commandment to heal.
-
Great latitude is permitted for learning.
-
The world is uncompleted and requires human participation to become
whole.
Catholic bioethicist Albert Jonsen, one of the deans of the field, gave
a historical perspective on the cloning debate, citing a paper by Joshua
Lederburg in the 1960s, which challenged his colleagues to look at the
implications of the then-remote possibility. He also traced the development
of Catholic views on other new medical technologies. When organ transplantation
was first introduced, it was opposed as a violation of the principal,
"First, do no harm" and as a mutilation of the human body. Later,
the issue was reconceived in terms of charity and concern for others.
One of the key questions, Jonsen suggested, is What can we, as a society
that promotes religious pluralism, do when we must make public policy
on issues where religious traditions may disagree. He argued that beneath
the particular teachings of each religion are certain broad themes they
share, which might provide a framework for the debate. These include human
finitude, human fallibility, human dignity, and compassion.
Ethics Perspectives
Lawrence Nelson, adjunct associate professor of philosophy at SCU, opened
the ethics panel with a discussion of the moral status of the human embryo.
Confining his remarks to viable, extracorporeal embryos (embryos created
for fertility treatments that were never implanted), Nelson argued that
these beings do have some moral status--albeit it weak--because they are
alive and because they are valued to varying degrees by other moral agents.
This status does entitle the embryo to some protection. In Nelsons
view, the gamete sources whose egg and sperm created these embryos have
a unique connection to them and should have exclusive control over their
disposition. If the gamete sources agree, Nelson believes the embryos
can be used for research if they are treated respectfully. Some manifestations
of respect might be:
-
They are used only if the goal of the research cannot be obtained
by other methods.
-
The embryos have not reached gastrulation (prior to 14 to 18 days
of development).
-
Those who use them avoid considering or treating them as property.
-
Their destruction is accompanied by some sense of loss or sorrow.
Philosophy Professor Barbara MacKinnon (University of San Francisco),
editor of Human Cloning: Science, Ethics, and Public Policy, began
by discussing the distinction between reproductive and therapeutic cloning
and the slippery slope argument. She distinguished three different forms
of this argument and showed that for each, pursuing stem cell research
will not inevitably lead to human reproductive cloning. MacKinnon favored
a continuing ban on the latter, citing safety concerns. Regarding therapeutic
cloning and stem cell research, she criticized consequentialist views
such as that anything can be done to reduce human suffering and that certain
embryos would perish anyway. However, she noted that non-consequentialist
concerns must also be addressed for therapeutic cloning, among them the
question of the moral status of the early embryo. She also made a distinction
between morality and the law, arguing that not everything that is immoral
ought to be prohibited by law, and showed how this position relates to
human cloning.
Paul Billings, co-founder of GeneSage, has been involved in crafting
an international treaty to ban human reproductive cloning and germ-line
genetic engineering. As arguments against human cloning he cited:
-
There is no right to have a genetically related child.
-
Cloning is not safe.
-
Cloning is not medically necessary.
-
Cloning could not be delivered in an equitable manner.
Billings also believes that the benefits of stem cell therapies have
been "wildly oversold." Currently, he argues, there are no effective
treatments coming from this research. He is also concerned about how developing
abilities in nuclear transfer technology may have applications in germ-line
genetic engineering that we do not want to encourage. As a result, he
favors the current go-slow approach of banning the creation of new cell
lines until some therapies have been proven effective. At the same time,
he believes we must work to better the situation of the poor and marginalized
so their access to all therapies is improved.
Legal Perspectives
Member of the State Advisory Committee on Human Cloning Henry "Hank"
Greely addressed some of the difficulties in creating a workable regulatory
system for human reproductive cloning. First he addressed safety, which,
considering the 5 to 10 times greater likelihood of spontaneous abortion
in cloned sheep, he argued clearly justifies regulation. The FDA has currently
claimed jurisdiction over this technology, but Greely doubted whether
the courts would uphold this claim. Given these facts, Greely saw three
alternatives for the state of California:
-
Do nothing; let the federal government take care of it.
-
Create an FDA equivalent to regulate the safety of the process, an
alternative he pointed out for which the state has no experience.
-
Continue the current ban on the grounds of safety until such time
as the procedure is adjudged safe. Next Greely responded to suggestions
that the state might regulate by distinguishing between prospective
cloners on the basis of their motivation, for example, denying a request
to clone a person to provide heart tissue for another person but okaying
a request if cloning were the only opportunity a couple might have
to conceive a child. Greely found the idea of the state deciding on
such basis deeply troubling because it would necessitate "peering
into someones soul" in a manner that government is not
adept at doing.
The impact of regulation on universities was the focus of Debra Zumwalts
presentation. As Stanford University general counsel, Zumwalt talked about
the necessity of creating regulations that are clear and simple. Currently,
federal regulations on stem cells are unclear, she argued, making it difficult
for universities and other institutions to tell if they are in compliance.
She believes that regulations should be based on science and good public
policy rather than on politics. As a result, she favored overall policy
being set by the legislature but details being worked out at the administrative
level by regulatory agencies with expertise. Whatever regulations California
develops should not be more restrictive than the federal regulations,
she warned, or research would be driven out of the state. Like several
other speakers, Zumwalt was concerned about federal regulations restricting
stem cell research to existing cell lines. That, she feared, would drive
all research into private hands. "We must continue to have a public
knowledge base," she said. Also, she praised the inherent safeguards
in academic research including peer review, ethics panels, and institutional
review boards.
SCU Presidential Professor of Ethics and the Common Good June Carbone
looked at the role of California cloning decisions in contributing to
the governance of biotechnology. California, she suggested, cannot address
these issues alone, and thus might make the most useful contribution by
helping to forge a new international moral consensus through public debate.
Taking a lesson from U.S. response to recent terrorist attacks, she argued
for international consensus based on the alliance of principle and self-interest.
Such consensus would need to be enforced both by carrot and stick and
should, she said, include a public-private partnership to deal with ethical
issues. Applying these ideas to reproductive cloning, she suggested that
we think about which alliances would be necessary to prevent or limit
the practice. Preventing routine use might be accomplished by establishing
a clear ethical and professional line prohibiting reproductive cloning.
Preventing exceptional use (a determined person with sufficient money
to find a willing doctor) might not be possible. As far as stem cell research
is concerned, Carbone argued that the larger the investment in such research,
the bigger the carrot--the more the funder would be able to regulate the
process. That, she suggested, argues for a government role in the funding.
If the professional community does not respect the ethical line drawn
by politicians, and alternative funding is available from either public
sources abroad or private sources at home, the U.S. political debate runs
the risk of becoming irrelevant.
"California Cloning" was organized by the Markkula Center
for Applied Ethics and co-sponsored by the Bannan
Center for Jesuit Education and Christian Values; the
Center for Science, Technology, and Society; the
SCU School of Law; the
High Tech Law Institute; the Howard
Hughes Medical Institute Community of Science Scholars Initiative;
and the law firm of Latham & Watkins.
Source: Santa Clara University
For more information about Human Cloning, visit the INReview Human Cloning Forum.